Research Article

Imported Malaria in Portugal 2000–2009: A Role for Hospital Statistics for Better Estimates and Surveillance

Ana Glória Fonseca,1 Sara S. Dias,1,2 João Luis Baptista,3 and Jorge Torgal1

1Public Health Department, Nova Medical School, Nova Lisbon University, Campo Mártyres da Pátria 130, 1169-056 Lisbon, Portugal
2UIS-ESSLei-IPLeiria, Campus 2, Morro do Lena, Apartado 4137, 2411-901 Leiria, Portugal
3Faculty of Health Sciences, Beira Interior University, Avenue Infante D. Henrique, 6200-506 Covilhã, Portugal

Correspondence should be addressed to Ana Glória Fonseca; ana.fonseca@fcm.unl.pt

Received 23 July 2014; Revised 3 October 2014; Accepted 17 November 2014; Published 7 December 2014

Academic Editor: Neena Valecha

Background. Although eradicated in Portugal, malaria keeps taking its toll on travelers and migrants from endemic countries. Disease notification is mandatory but is compromised by underreporting.

Methods. A retrospective study on malaria hospitalizations for 10 consecutive years (2000–2009) was conducted. Data on hospitalizations and notifications were obtained from Central Administration of Health System and Health Protection Agency, respectively. For data selection ICD-9CM and ICD-10 were used: codes 084∗, 647.4, and B50–B54. Variables were gender, age, agent and origin of infection, length of stay (LOS), lethality, and comorbidities. Analysis included description, hypothesis testing, and regression.

Results. There were 2003 malaria hospitalizations and 480 notified hospitalized cases, mainly in young male adults. P. falciparum was the main agent of infection acquired mainly in sub-Saharan Africa. Lethality was 1.95% and mean LOS was 8.09 days. Older age entailed longer LOS and increased lethality.

Discussion. From 2000 to 2009, there were 2003 malaria hospitalizations with decreasing annual incidence, these numbers being remarkably higher than those notified. The national database of diagnosis related groups, reflecting hospitalizations on NHS hospitals, may be an unexplored complementary source for better estimates on imported malaria.

1. Introduction

Outside endemic regions, malaria may occur in travellers that have recently been to or visited endemic regions or in individuals from endemic countries recently arrived at or visiting nonendemic regions. Imported malaria is therefore defined as “an infection that was acquired in an endemic area by an individual (either a tourist or indigenous native) but diagnosed in a nonendemic country after development of the clinical disease” [1].

The increase in international travel and climate changes are considered important causes for the emergence of imported malaria. International travel to malarial zones is estimated at 80–90 million travellers annually and results in an estimated 30000 annual imported malaria cases worldwide [2, 3].

Since the year 2000 and contrary to the trend in the preceding years, there has been a progressive and steady decrease in the annual incidence of imported malaria that varied from 15303 reported cases in the World Health Organization (WHO) European Region in 2000 to 5712 in 2009 [4]. Those promptly diagnosed and treated generally have a full recovery, making imported malaria an avoidable cause of death that nevertheless still accounts for a considerable preventable burden of morbidity and mortality every year in nonendemic countries.

WHO declared autochthonous malaria eradicated in Portugal in 1973 [5]. However, due to increasing international travel and travel related to extensive international cultural and commercial relations, malaria keeps taking its toll on travelers and migrants to and from endemic countries. Disease surveillance consists of a physician based passive case detection system liable to underreporting. National data on imported malaria are scarce or nonexistent, the available data being based on sporadic single hospital based or regional based case series and case reports [5–9].
Complementing notification data may allow for better malaria burden estimates. Imported hospitalized malaria cases from 2000 to 2009 were analysed at national level, using Portugal’s Diagnosis Related Groups (DRG) information system from National Health Services (NHS) hospital episodes statistics and Statutory Notification information system. Frequency of occurrence, hospital length of stay, lethality, plasmodium species, and origin of infection were considered. Secondly, the influence of demographic factors and comorbidities on in-hospital length of stay and lethality were analyzed.

2. Methods

A retrospective study was conducted, using Portuguese National Diagnosis Related Groups (DRG) database, resulting from the NHS hospital episodes statistics, and the National Statutory Notifiable Disease Surveillance database, resulting from disease notification, provided by the Central Administration of Health System (ACSS) and the Health Protection Agency (HPA), respectively. The data were made anonymous for analysis.

In the DRG database each record corresponds to a National Health Service (NHS) hospital discharge episode (hospitalization). The Diagnostic Related Groups (DRG) were developed as an inpatient classification system that determines the payment allocated to the hospital [10]. It provides a complete record of all hospitalizations and is not compromised by the limitations of existent surveillance systems, such as under diagnosis or deficiencies in reporting. Within DRGs the 9th International Classification Disease Clinical Modification (ICD-9 CM) is used to classify all diagnosis assigned by the physician at discharge. Malaria diagnosis implies laboratorial microscopic parasite detection and/or antigen parasite detection test for Plasmodium falciparum and nonfalciparum infections. Molecular PCR technology is not widely available but is possible in some institutions, mainly those involved in research.

Malaria surveillance, on the other hand, is a passive mandatory physician based case detection system in Portugal resulting in the National Statutory Notifiable Disease Surveillance database [11]. A standardised paper notification form, equal to all notifiable diseases, is used. During the period of study only confirmed cases were notified. There is no laboratory based notification system. In the National Statutory Notifiable Disease Surveillance database each record corresponds to a case of disease. The 10th International Classification Disease (ICD-10) is used to classify diagnosis.

The study population was selected using ICD-9 CM, codes 084 (malaria) [namely 084.0 (Plasmodium falciparum), 084.1 (Plasmodium vivax), 084.2 (Plasmodium malariae), 084.3 (Plasmodium ovale), 084.5 (mixed malaria), 084.6 (malaria unspecified), and 084.9 (pernicious complication)] and 647.4 (malaria in the mother classifiable elsewhere, but complicating pregnancy, childbirth, or the puerperium), for the DRG database and 10th International Classification Disease (ICD-10), codes B50 (Plasmodium falciparum), B51 (Plasmodium vivax), B52 (Plasmodium malariae), B53.0 (Plasmodium ovale), and B54 (malaria unspecified), for the National Statutory Notifiable Disease Surveillance database.

Data on malaria cases is nationwide and covers a 10-consecutive-year study period (2000–2009). Variables from de DRG database included gender, age, year of hospitalization, month of hospitalization, district of patient’s residence, in-hospital length of stay (LOS), and lethality. Variables from the statutory notification database included year of notification, agent and origin of infection, and lethality. Certain characteristics, such as nationality and whether they are travelers, immigrants, expatriates, or visiting friends and relatives (VFRs), treatment schedule, chemoprophylaxis use, and duration of travel in endemic countries, could not be retrieved from the databases because these items are not systematically collected.

In the DRG database, potential factors influencing LOS or death were defined: (a) age > 64 years; (b) gender; (c) malaria related to pregnancy (ICD-9 code 064.74); (d) HIV infection (ICD-9 code 042); (e) other infections excluding malaria (ICD-9 codes 001–009, 011–018, 020–027, 030–040, 042, 060–066, 070, 071, 082, 083, 085, 086, 091–095, 098, 100, 120–129, and 130); (f) pneumonia (ICD-9 codes 480–486); (g) respiratory failure (ICD-9 codes 518.81–518.84); (h) chronic obstructive pulmonary disease (ICD-9 codes 490–496); (i) diabetes mellitus (ICD-9 code 250); (j) arterial hypertension (ICD-9 codes 401–405); (k) renal failure (ICD-9 codes 584, 585, 586, 403, and 404); (l) anemia (ICD-9 codes 280–285); (m) thrombocytopenia (ICD-9 codes 287.4–287.5).

The demographic characteristics of the patients were summarised using mean and standard deviation (SD) and medians and interquartile range (IQR) for continuous data and using proportions for categorical data. Hypothesis testing was used to compare groups: t-tests and ANOVA, assuming normal distribution for continuous data; chi-square test or Fisher exact test (if the expected values were too small) for categorical data. Linear regression model was used to study the length of stay and logistic regression model used to study the effect on lethality. Due to the skewed length of stay data, a log transformation was carried out to normalise the data before multivariate analysis; this procedure is usual for such data [12, 13]. Although gender and age are not statistically significant at the 5% level, they were retained in the model in order to control for possible confounding. Covariates controlled in multivariate analysis were the potential factors defined before. The effect sizes from the multivariate analysis are reported as relative ratios (exponential of the regression coefficient of the log transformed data) for the in-hospital length of stay and as odds ratio (OR) for lethality. Confidence intervals are given at 95% and P values less than 0.05 are statistically significant, although the multivariate final models include covariates with 10% significance level in the univariate analysis. Data were analysed using R software, namely, glm library.

3. Results

Table 1 summarizes the general descriptive demographic and epidemiological characteristics, considering hospitalizations
Table 1: Demographic/general characteristics.

| Gender (n, %)          | NHS hospitalizations (DRG database) | Statutory hospitalized notifications |
|------------------------|-------------------------------------|-------------------------------------|
| Female                 | 587, 29%                           | 376, 78.3%                          |
| Male                   | 1416, 71%                          | 104, 21.7%                          |
| Age (years)            |                                     |                                     |
| Mean                   | 37.7                               | 38.5                                |
| Median                 | 38                                 | 38                                  |
| Standard deviation     | 17.019                             | 15.46                               |
| Minimum; maximum       | 0; 98                              | 0; 85                               |
| Month of hospitalization (n, %) | —                              | —                                   |
| January                | 202, 10.1%                         |                                     |
| February               | 132, 6.6%                          |                                     |
| March                  | 126, 6.3%                          |                                     |
| April                  | 165, 8.2%                          |                                     |
| May                    | 193, 9.6%                          |                                     |
| June                   | 207, 10.3%                         |                                     |
| July                   | 161, 8.0%                          |                                     |
| August                 | 154, 7.7%                          |                                     |
| September              | 156, 7.8%                          |                                     |
| October                | 150, 7.5%                          |                                     |
| November               | 154, 7.7%                          |                                     |
| December               | 203, 10.1%                         |                                     |
| Agent of infection (n, %) | —                              | —                                   |
| *Plasmodium falciparum*| 328, 68.3%                         |                                     |
| *Plasmodium vivax*     | 40, 8.3%                           |                                     |
| *Plasmodium ovale*     | 5, 1.04%                           |                                     |
| *Plasmodium malariae*  | 5, 1.04%                           |                                     |
| *Plasmodium sp. not specified* | 103, 21.4% |                                     |
| Origin of infection    |                                     |                                     |
| Sub-Saharan Africa     | 352, 73.33%                        |                                     |
| Central Continental America | 1, 0.21% |                                     |
| Tropical South America | 6, 1.25%                           |                                     |
| South-Eastern Asia     | 18, 3.75%                          |                                     |
| South-Central Asia     | 5, 1.04%                           |                                     |
| Not specified           | 98, 20.42%                         |                                     |
| Length of stay (days)  |                                     |                                     |
| Mean                   | 8.09                               |                                     |
| Median                 | 6                                  |                                     |
| Standard deviation     | 10.85                              |                                     |
| Minimum; maximum       | 0; 168                             |                                     |
| Lethality (n, %)       | 39, 1.95%                          | 16, 3.3%                            |
| Total (n, %)           | 2003, 100%                         | 480, 100%                           |

Figure 1: Imported malaria hospitalizations and deaths (NHS DRG database) and notifications of hospitalized cases and deaths (Statutory Notifiable Disease database) in Portugal 2000–2009.

3.1. Imported Malaria Hospitalizations at NHS Hospitals (DRG Database). From 2000 to 2009, there were 2003 hospitalizations with malaria diagnosis, the annual incidence declining from 314 hospitalizations in 2000 to 130 in 2009. Most cases were male (1416, 71%) aged 18–64 years (1650, 82.4%, mean age 37.7 years), with residence at Lisbon (986, 49.2%), Setubal (169, 8.4%), and Porto (259, 12.9%). In-hospital mean length of stay (LOS) was 8.09 days and lethality was 1.95% (39/2003).

In the first four years the annual number of malaria hospitalizations was significantly higher than in the following years (chi-square test $P < 0.001$). Mean length of stay remained stable throughout the years, varying from 6.88 days to 9.39 days, the annual variation not being significantly different (ANOVA test $P > 0.05$). Lethality remained relatively stable, ranging from 0.75% to 3.85%, with peaks in 2001 (2.5%), 2007 (3.3%), and 2009 (3.5%). Those who died had a significantly higher mean length of stay (20.5 days for those who died and 7.84 days for those who did not die, $t$-test, $P < 0.001$).

In January, May, June, and December (202, 193, 207, and 203 cases resp.), observed cases exceeded by 26 to 40 those expected. On the contrary, in February and March (132 and 126) the frequency of cases was 35 and 40 lower than expected (chi-square test $P < 0.001$). Mean length of stay ranged from 6.77 days in September to 9.32 days in April but no significant differences were observed (ANOVA $P > 0.05$). Absolute mortality and lethality were the highest in March ($n = 5$, 3.97%) and the lowest in September ($n = 1$, 0.64%).

On age analysis, more than 75–80% of annual hospitalizations were on those aged 18–64 years. Older age (>64 years old) corresponded to 5.9% (119) of all hospitalizations and younger age (<18 years old) corresponded to 11.7% (234). Older age (>64 years old) had significantly higher mean length of stay (11.45 days versus 7.88 days, $t$-test, $P = 0.001$) and lethality (10% versus 1.43%, Fisher’s exact test, $P < 0.001$).
Between 2000 and 2009, there were 541 confirmed malaria statutory notifications (480 hospitalized cases, 42 ambulatory cases, and 19 not known). From the 480 notifications referring to hospitalized cases, most were in males (376, 78.3%), mean age was 38.5 years, and in 16 cases outcome was death (3.33%). Within these \( n = 480 \), 

### Table 2: Prevalence and length of stay considering predefined comorbidities, on univariate and multivariate analysis.

| Variables                        | Prevalence N (%) | Mean LOS Days | Log LOS Unadjusted—RR (CI) P | Log LOS Adjusted—RR (CI) P |
|----------------------------------|------------------|---------------|-------------------------------|----------------------------|
| Female gender                    | 587 (29%)        | 8.15 versus 8.07, 0.875 | 0.985 (0.908–1.068), 0.71 | 0.956 (0.886–1.031), 0.242 |
| Age > 64 (LOS)                   | 119 (5.94)       | 11.2 versus 7.88, 0.001 | 1.005 (1.003–1.007), <0.001 | 1.296 (1.116–1.504), 0.001 |
| Malaria related to pregnancy     | 37 (1.84)        | 8.41 versus 8.08, 0.85 | 1.049 (0.797–1.381), 0.732 |
| HIV infection                    | 50 (2.50)        | 18.4 versus 7.83, <0.001 | 2.293 (1.813–2.898), <0.001 | 1.233 (0.859–1.470), 0.395 |
| Other infections                 | 145 (7.25)       | 17.93 versus 7.32, <0.001 | 2.214 (1.927–2.542), <0.001 | 1.853 (1.576–2.181), <0.001 |
| Pneumonia                        | 78 (3.89)        | 18.3 versus 7.6, <0.001 | 2.477 (2.054–2.986), <0.001 | 1.824 (1.507–2.210), <0.001 |
| Respiratory failure              | 89 (4.44)        | 19 versus 7.6, <0.001 | 2.284 (1.916–2.724), <0.001 | 1.464 (1.212–1.770), <0.001 |
| Chronic obstructive pulmonary disease | 35 (1.75)    | 12.66 versus 8.01, 0.012 | 1.464 (1.104–1.941), 0.008 | 1.213 (0.931–1.578), 0.151 |
| Diabetes mellitus                | 92 (4.60)        | 9.23 versus 8.04, 0.304 | 1.293 (1.083–1.542), 0.004 | 1.108 (0.936–1.313), 0.232 |
| Arterial hypertension            | 139 (7.0)        | 19.17 versus 8.01, 0.226 | 1.184 (1.024–1.370), 0.023 | 1.054 (0.918–1.212), 0.457 |
| Renal failure                    | 90 (4.50)        | 16.1 versus 7.7, <0.001 | 1.759 (1.474–2.100), <0.001 | 1.176 (0.985–1.405), 0.090 |
| Anemia                           | 426 (21.27)      | 11.8 versus 7.09, <0.001 | 1.592 (1.458–1.738), <0.001 | 1.473 (1.353–1.603), <0.001 |
| Thrombocytopenia                 | 374 (18.67)      | 7.37 versus 8.26, 0.155 | 1.078 (0.02–0.170), 0.12  |<|  

\( P < 0.001 \) for mean length of stay (LOS) and lethality. This association prevailed on multivariate analysis for age, other infections, pneumonia, respiratory failure, chronic obstructive lung disease, diabetes, arterial hypertension, renal failure, anemia, and thrombocytopenia) ranged from 1.84% (malaria related to pregnancy) to 21.27% (anemia).

### 3.3. Factors Influencing Length of Stay and Mortality (Tables 2 and 3).

Considering NHS malaria hospitalizations \( n = 352 \), the frequency of predefined comorbidities (age > 64, pregnancy related malaria, HIV infection, other infections excluding malaria, pneumonia, respiratory failure, chronic obstructive lung disease, diabetes, arterial hypertension, renal failure, anemia, and thrombocytopenia) ranged from 1.84% (malaria related to pregnancy) to 21.27% (anemia).

#### 3.3.1. Length of Stay (LOS).

The overall in-hospital mean length of stay was 8.09 days and the median was 6 (IQR 4–8). On univariate analysis, the following variables were associated with prolonged length of stay: age > 64 years, HIV infection, other infections excluding malaria, pneumonia, respiratory failure, chronic obstructive lung disease, diabetes, arterial hypertension, renal failure, anemia, and thrombocytopenia. Compared to those without infection the adjusted relative ratio (RR) for other infections was 1.85 (95% CI 1.57–2.18) followed by pneumonia (RR = 1.82, 95% CI 1.51–2.21). Respiratory failure has a high RR in unadjusted and adjusted analysis, although it reduces after adjusting for possible confounding factors.
Factors were considered together.

On the contrary, age > 64 further increased length of stay when other factors were considered together.

### 3.3.2. Lethality

The overall in-hospital lethality was 1.95% (39/2003). On univariate analysis, the following variables were associated with increased lethality: age > 64 years, HIV infection, other infections, diabetes, pneumonia, respiratory failure, and renal failure. This association prevailed on multivariate regression analysis for age > 64, respiratory failure, and renal failure. In comparison to those without respiratory failure the adjusted odds ratio was 32.79 (95% CI 13.16–81.70), followed by age > 64 years (OR = 5.37, 95% CI 2.14–13.50). The OR of the significant comorbidities decreased when the other factors were considered together.

### 4. Discussion

Between 2000 and 2009, there were 2003 malaria admissions to NHS hospitals in Portugal. The data show a consistent declining annual trend contrasting with a relative stability in mean length of stay and lethality observed in the same period. Overall in-hospital lethality was 1.95% and mean length of stay was 8.09 days.

This decreasing incidence of imported malaria despite increasing global international travel (malaria endemic regions included) is in contrast with the steady increase until the year 2000 and has been observed in other countries in Europe [4, 14, 15]. Reductions on malaria transmission have been achieved in many malaria endemic countries, as malaria control programmes have been successfully implemented [16, 17]. Nevertheless, malaria hospitalizations are known to have increased since 2009 in Portugal, increased expatriation to malaria endemic countries being one plausible explanation [18].

For the same time period (2000–2009), National Statutory malaria notification consisting mainly of hospitalized cases (480, 88.7% of total malaria notifications) only captured a quarter of total hospitalizations and indicated stable annual case frequency (40–50 per year), contradicting the declining trend observed for NHS hospitalizations. This denotes very high malaria underreporting, moreover considering that many malaria cases are treated without hospital stay and therefore are not included in the DRG database.

Malaria underreporting is not new but is worrying. Underreporting estimates of imported malaria in Europe ranged from 20 to 59% [19]. In Portugal there are no quantified estimates. Malaria is included in the National Notifiable Infectious Diseases Surveillance Programme, a passive clinician based mandatory surveillance system. The notification process is not very user friendly and the time involved in completing the different steps in the system compromises timeliness. It consists of manually filling in a specific notification paper form, common for all notifiable infectious diseases, and parasite confirmation is microscopic and/or by antigen detection test [1, 2]. There is no laboratory based notification, contrary to other European countries which have better reporting performances or improved them on including such notification [1, 20–23]. The notification paper forms are frequently not readily available in the institutions and have to be sent by post. As such, with the daily hustle bustle demands of patient care, clinicians may easily forget to do it, furthermore considering they might not be fully aware that malaria is included in the notifiable disease list or of the legal requirement to report. The use of a notification paper form, common to all notifiable infectious diseases, and parasite confirmation is microscopic and/or by antigen detection test [1, 2]. There is no laboratory based notification, contrary to other European countries which have better reporting performances or improved them on including such notification [1, 20–23]. The notification paper forms are frequently not readily available in the institutions and have to be sent by post. As such, with the daily hustle bustle demands of patient care, clinicians may easily forget to do it, furthermore considering they might not be fully aware that malaria is included in the notifiable disease list or of the legal requirement to report. The use of a notification paper form, common to all notifiable infectious diseases, and parasite confirmation is microscopic and/or by antigen detection test [1, 2]. There is no laboratory based notification, contrary to other European countries which have better reporting performances or improved them on including such notification [1, 20–23]. The notification paper forms are frequently not readily available in the institutions and have to be sent by post. As such, with the daily hustle bustle demands of patient care, clinicians may easily forget to do it, furthermore considering they might not be fully aware that malaria is included in the notifiable disease list or of the legal requirement to report.

### Table 3: Prevalence and lethality considering predefined comorbidities, on univariate and multivariate analysis.

| Variables                        | Prevalence | Lethality |
|----------------------------------|------------|-----------|
|                                  | N (%)      | OR unadjusted (CI) | Lethality |
| Female gender                    | 587 (29%)  | 0.829 (0.401–1.712) | 0.612     |
| Age > 64                         | 119 (5.94) | 7.713 (3.802–15.648) | <0.001†   |
| Malaria related to pregnancy     | 37 (1.84)  | 2.979 (0.691–12.849) | 0.161†    |
| HIV infection                    | 50 (2.50)  | 3.399 (1.011–11.430) | 0.071†    |
| Other infections                 | 145 (7.24) | 4.672 (2.230–9.798) | <0.001†   |
| Pneumonia                        | 78 (3.89)  | 8.239 (3.767–18.022) | <0.001†   |
| Respiratory failure              | 89 (4.44)  | 60.349 (29.626–122.935) | <0.001†   |
| Chronic obstructive pulmonary disease | 35 (1.75) | 3.970 (1.620–9.730) | 0.008†    |
| Diabetes mellitus                | 92 (4.60)  | 2.008 (0.773–5.219) | 0.188†    |
| Arterial hypertension            | 139 (6.94) | 20.017 (10.195–39.302) | 0.001†    |
| Renal failure                    | 90 (4.50)  | 21.078 (10.195–39.302) | 0.001†    |
| Anemia                           | 426 (21.27)| 1.466 (0.724–2.970) | 0.285     |
| Thrombocytopenia                 | 374 (18.67)| 1.127 (0.514–2.471) | 0.766     |

†Fisher exact test due to small expected values.
of notification, and concerns regarding confidentiality have been identified elsewhere and can easily apply to Portugal [24, 25]. This study confirms that malaria underreporting is an issue and it needs to be thoroughly addressed to uncover its reasons and implement strategies to overcome it. Reporting timeliness delays, data quality and completeness of data, cumbersome reporting process, and lack of laboratorial notification, as discussed above, are other limitations to consider in addition to the scarcity of systematic malaria surveillance activities evaluation. Electronic Internet based reporting systems are considered more efficient with proven benefits in terms of timeliness and completeness compared to conventional systems and are already in use in some countries [26–28]. In Portugal, the implementation of the National Epidemiology Surveillance System, an electronic national surveillance system including infectious diseases and other public health risks, is starting and improvements in reporting performance are expected [29].

Cases showed a bimodal pattern with peaks in May–June and December-January not combined with mortality peaks. Sub-Saharan Africa was the main origin of imported infection in Portugal as observed in this and others studies [5, 6, 8].

Most cases occurred in working age male adults, a gender and age predominance observed in other European and non-European countries [3, 15, 30–32]. No male predominance was observed for length of stay or lethality though. Increasing age was strongly and independently associated with higher length of stay but did not increase lethality. The data however do not allow a severity stratified analysis as other WHO criteria for severity could not be retrieved from DRG database. Pneumonia and other infections significantly increased length of stay but not lethality. Coinfections, namely, pneumonia and bacteremia, community acquired or nosocomial, are not infrequent in hospitalized malaria, especially in severe cases, and may affect management and outcome [8, 39].

None of the chronic diseases analysed (HIV infection, chronic pulmonary disease, diabetes mellitus, and arterial hypertension) seemed to have an effect neither on length of stay nor on lethality, their prevalence ranging from 1.75% to 6.94%. The data on chronic diseases, such as diabetes mellitus and arterial hypertension, and on the severity of imported malaria are scarce. Their frequency does increase with increasing age though, and age is an independent risk factor for mortality as shown here and elsewhere [33–35]. Generally, the association of HIV infection and imported malaria has not consistently been related to worse outcome, its impact on malaria severity depending on the severity of the immunosuppression [40–43].

Malaria outcome depends on many factors, as retrieved from sentinel surveillance data, hospital based case series (hospital clinical records), and surveillance data analysis in countries with organized malaria surveillance programs. These include nationality, traveler characteristics (e.g., expatriate, immigrant, VFR, etc.), geographic origin, travel destination, adhesion to chemoprophylaxis, delays in seeking medical care, delays in diagnosis and treatment of suspected malaria, and treatment schedule that could not be included in multifactorial analysis because they are not included in the database [33, 44]. The results obtained however suggest that some comorbidities may prolong the length of stay and increase lethality.

There are limitations associated with the use of DRG data. The information on hospital characteristics was not gathered for epidemiological purposes; some vital features of malaria patients are missing and therefore it does not allow for the analysis of variables usually seen in epidemiologic studies. The DRG data cannot account for multiple admissions, reducing our experimental unit to discharge episode instead of patient. Its use however allows for obtaining timely nationwide data without the constraints and limitations of surveillance systems, such as under diagnosis or underreporting, providing data that would be otherwise unfeasible or logistically, cumbersome, difficult, and expensive to obtain.

Malaria is not easily subject to miscoding, due to diagnosis specificities (parasite detection by microscopy, antigen detection tests, or molecular PCR technology), though malaria subtypes may not be accurately or specifically discriminated on codification; therefore no such subtype analysis was done within the DRG database.

The use of hospital episode statistics, such as DGR database, for research and epidemiological purposes in infectious and noninfectious diseases, being able to congregate data at local and national level, is not original though results have to be analyzed considering the specificities of the disease under study, data quality and coding accuracy, and advantages and limitations of the database [45].
5. Conclusions

This is to our knowledge the first comprehensive national level study on imported malaria in Portugal and one that provides new insight on malaria burden estimates, particularly concerning malaria treated in hospitals, using the national databases available. Hospitalized malaria notifications reflected a quarter of NHS malaria hospitalizations and less than half of in-hospital lethality. Older age significantly increased hospital stay and lethality, and comorbidities are suggested as significant influencing factors. *P. falciparum* was the main plasmodium species responsible for the malaria cases and sub-Saharan Africa is the main geographic region of infection.

Along with climate change, international travel is thought to increase the risk of imported malaria, making malaria surveillance an important pillar of public health protection. Hospital statistics episodes (DRG database) analysis may be an unexplored complementary resource, in addition to statutory notification, for imported malaria surveillance in Portugal, especially considering the nonquantified underreporting, the increasing international travel, and the recent boost in emigration to malaria endemic regions in Portugal.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors thank the Central Administration of Health System (ACSS) and the Health Protection Agency (HPA) for the Portuguese National database of the Diagnosis Related Groups (DRG) resulting from NHS hospital episodes and the National Statutory Notifiable Disease Surveillance database.

References

[1] P. Muentener, P. Schlagenhauf, and R. Steffen, “Imported malaria (1985–95): trends and perspectives,” *Bulletin of the World Health Organization*, vol. 77, no. 7, pp. 560–566, 1999.

[2] P. Schlagenhauf and E. Petersen, “Malaria chemoprophylaxis: strategies for risk groups,” *Clinical Microbiology Reviews*, vol. 21, no. 3, pp. 466–472, 2008.

[3] M. P. Nelder, C. Russell, D. Williams et al., “Spatiotemporal dynamics and demographic profiles of imported *Plasmodium falciparum* and *Plasmodium vivax* infections in Ontario, Canada (1990–2009),” *PLoS ONE*, vol. 8, no. 9, Article ID e76208, 2013.

[4] World Health Organization—Regional Office for Europe, *Information System for Infectious Diseases (CISID)*, 2014, http://data.euro.who.int/cisid/?TabID=326594.

[5] L. Castro, A. I. Cardoso, L. Queirós, and G. Gonçalves, “Malária na Região Norte de Portugal (1993–2002),” *Acta Médica Portuguesa*, vol. 17, no. 4, pp. 291–298, 2004.

[6] S. Ferreira, R. Barros, P. Leuschner, P. Paiva, and P. Barbosa, “Malária importada em Portugal-experiência de um Hospital do Norte do País,” *RPDI*, vol. 5, no. 1, pp. 25–30, 2009.

[7] S. Freira, C. Luís, M. Brito, and C. Santos, “Internamento por malária importada em crianças, em dois hospitais da Grande Lisboa,” *Acta Pediátrica Portuguesa*, vol. 40, no. 2, pp. 65–68, 2009.

[8] L. C. Santos, C. F. Abreu, S. M. Xerinda, M. Tavares, R. Lucas, and A. C. Sarmento, “Severe imported malaria in an intensive care unit: a review of 59 cases,” *Malaria Journal*, vol. 11, article 96, 2012.

[9] I. Palma Dos Reis, C. Serafim, B. Valério et al., “Malária Grave Importada em Doentes Críticos,” *Acta Médica Portuguesa*, vol. 25, no. 5, pp. 271–276, 2012.

[10] C. Borges, *Grupos de Diagnósticos Homogéneos (GDH)*, ACSS, 2014, http://www.acss.min-saude.pt/%C3%81reaUnidades/DepartamentoGest%C3%A3oFinanciamentoPresta%C3%B-Ade/SClassifica%C3%A7%C3%A3odoenetes/Gruposdiagn%C3%B3sticosHomog%C3%A9neos/tabid/460/language/pt-PT/Default.aspx.

[11] Diário da República, Portaria 1071/98 de 31 de Dezembro, DR no. 301, I Série B, 1998.

[12] S. K. Ng, K. K. Yau, and A. H. Lee, “Modelling inpatient length of stay by a hierarchical mixture regression via the EM algorithm,” *Mathematical and Computer Modelling*, vol. 37, no. 3–4, pp. 365–375, 2003.

[13] K. E. Barbour, A. Fabio, and D. N. Pearlman, “Inpatient charges among HIV/AIDS patients in Rhode Island from 2000–2004,” *BMC Health Services Research*, vol. 9, no. 1, article 3, 2009.

[14] G. Sabatinelli, M. Ejob, and P. Joergensen, “Malária in the WHO European Region (1971–1999),” *Euro Surveillance*, vol. 6, no. 4, pp. 61–65, 2001.

[15] G. G. van Rijckevorsel, G. J. Sonder, R. B. Geskus et al., “Declining incidence of imported malaria in the Netherlands, 2000–2007,” *Malaria Journal*, vol. 9, no. 1, article 300, 2010.

[16] A. M. Noor, D. K. Kinyoki, C. W. Mundia et al., “The changing risk of *Plasmodium falciparum* malaria infection in Africa: 2000–10: a spatial and temporal analysis of transmission intensity,” *The Lancet*, vol. 383, no. 9930, pp. 1739–1747, 2014.

[17] S. I. Hay, C. A. Guerra, A. J. Tatem, A. M. Noor, and R. W. Snow, “The global distribution and population at risk of malaria: past, present, and future,” *The Lancet Infectious Diseases*, vol. 4, no. 6, pp. 327–336, 2004.

[18] A. G. Fonseca, S. S. Dias, J. L. Baptista, and J. Torgal, “The burden of imported Malaria in Portugal 2003 to 2012,” *Journal of Travel Medicine*, vol. 21, no. 5, pp. 354–356, 2014.

[19] F. Legros and M. Danis, “Surveillance of malaria in European Union countries,” *European Surveillance*, vol. 3, no. 5, pp. 45–47, 1998.

[20] N. A. H. van Hest, F. Smit, and J. P. Verhave, “Underreporting of notifiable infectious disease notifications in the Netherlands 1995–2003 assessed by capture-recapture,” *Epidemiology and Infection*, vol. 129, no. 2, pp. 371–377, 2002.

[21] H. W. Unger, A. D. McCallum, V. Ukachukwu et al., “Imported malaria in Scotland—an overview of surveillance, reporting and trends,” *Travel Medicine and Infectious Disease*, vol. 9, no. 6, pp. 289–297, 2011.

[22] G. M. Ong and B. Smyth, “Imported malaria to Northern Ireland: improving surveillance for better intervention,” *Ulster Medical Journal*, vol. 75, no. 2, pp. 129–135, 2006.

[23] S. Klein and A. Bosman, “Completeness of malaria notification in the Netherlands 1995–2003 assessed by capture-recapture methods,” *European Surveillance*, vol. 10, no. 10, pp. 244–246, 2005.

[24] E. D. Brabazon, A. O’farrell, C. A. Murray, M. W. Carton, and P. Finnegan, “Under-reporting of notifiable infectious disease
hospitalizations in a health board region in Ireland: room for improvement?" *Epidemiology and Infection*, vol. 136, no. 2, pp. 241–247, 2008.

[25] P. M. Konowitz, G. A. Petrossian, and D. N. Rose, "The underreporting of disease and physicians’ knowledge of reporting requirements," *Public Health Reports*, vol. 99, no. 1, pp. 31–35, 1984.

[26] M. Ward, P. Brandsema, E. van Straten, and A. Bosman, "Electronic reporting improves timeliness and completeness of infectious disease notification, The Netherlands, 2003," *Euro Surveillance*, vol. 10, no. 1, pp. 27–30, 2005.

[27] E. Jelastopulu, G. Merekoulias, and E. C. Alexopoulos, "Under-reporting of communicable diseases in the prefecture of Achaia, western Greece, 1999–2004—missed opportunities for early intervention," *Euro Surveillance*, vol. 133, no. 3, pp. 401–407, 2005.

[28] A. Jansson, M. Arneborn, and K. Ekdahl, "Sensitivity of the Swedish statutory surveillance system for communicable diseases 1998–2002, assessed by the capture-recapture method," *Epidemiology and Infection*, vol. 133, no. 3, pp. 401–407, 2005.

[29] Diario da República, Despacho no. 5855/2014 de 5 Maio, DR no. 85, II Serie, 2014.

[30] A. D. Smith, D. J. Bradley, V. Smith et al., "Imported malaria and high risk groups: observational study using UK surveillance data 1987–2006," *British Medical Journal*, vol. 337, article a120, 2008.

[31] D. M. Charles, J. Hart, W. A. Davis, E. Sullivan, G. K. Dowse, and T. M. E. Davis, “Notifications of imported malaria in Western Australia, 1990–2001: incidence, associated factors and chemoprophylaxis,” *Medical Journal of Australia*, vol. 182, no. 4, pp. 164–167, 2005.

[32] R. Romi, D. Boccolini, and G. Majori, "Malaria incidence and mortality in Italy in 1999–2000," *Euro Surveillance*, vol. 6, no. 10, pp. 143–147, 2001.

[33] F. Legros, O. Bouchaud, T. Ancelle et al., "Risk factors for imported fatal *Plasmodium falciparum* malaria, France, 1996–2003," *Emerging Infectious Diseases*, vol. 13, no. 6, pp. 883–888, 2007.

[34] A. M. Checkley, A. Smith, V. Smith et al., "Risk factors for mortality from imported falciparum malaria in the United Kingdom over 20 years: an observational study," *British Medical Journal*, vol. 344, Article ID e2116, 2012.

[35] N. Mühlberger, T. Jelinek, R. H. Behrens et al., "Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance data," *Clinical Infectious Diseases*, vol. 36, no. 8, pp. 990–995, 2003.

[36] WHO, *Guidelines for the Treatment of Malaria*, World Health Organization, Geneva, Switzerland, 2nd edition, 2010.

[37] Infarmed, *Formulário Hospitalar Nacional de Medicamentos*, http://www.infarmed.pt/formulario/.

[38] H. H. Asklng, F. Bruneel, G. Burchard et al., “Management of imported malaria in Europe,” *Malaria Journal*, vol. 11, article 328, 2012.

[39] F. Bruneel, F. Tubach, P. Corne et al., "Severe imported falciparum malaria: a cohort study in 400 critically ill adults," *PLoS ONE*, vol. 5, no. 10, Article ID e13236, 2010.

[40] M. E. Marks, M. Armstrong, M. M. Suvari et al., “Severe imported falciparum malaria among adults requiring intensive care: a retrospective study at the hospital for tropical diseases, London,” *BMC Infectious Diseases*, vol. 13, no. 1, article 118, 2013.